Icure Pharmaceutical Incorporation Cash Flow-to-Debt Ratio
Icure Pharmaceutical Incorporation cash flow-to-debt ratio. Icure Pharmaceutical Incorporation (175250) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2025, meaning its operating cash flow of ₩-3.28 Billion could theoretically repay 0% of its total liabilities (₩64.30 Billion) in one year. Check how high is Icure Pharmaceutical Incorporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Icure Pharmaceutical Incorporation (2015–2024)
Cash flow-to-debt ratio of Icure Pharmaceutical Incorporation from 2015 to 2024. Historical debt coverage capacity for Icure Pharmaceutical Incorporation across 10 annual periods. Check 175250 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Icure Pharmaceutical Incorporation Cash Flow-to-Debt Ratio by Year (2015–2024)
Icure Pharmaceutical Incorporation cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Icure Pharmaceutical Incorporation. For the full cash flow conversion analysis, see cash flow conversion of Icure Pharmaceutical Incorporation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.23x | ₩-17.05 Billion | ₩72.62 Billion | ▼ -85.1% |
| 2023 | -0.13x | ₩-13.52 Billion | ₩106.54 Billion | ▼ -51.2% |
| 2022 | -0.08x | ₩-11.28 Billion | ₩134.45 Billion | ▲ +61.7% |
| 2021 | -0.22x | ₩-26.23 Billion | ₩119.69 Billion | ▼ -46.6% |
| 2020 | -0.15x | ₩-12.40 Billion | ₩82.99 Billion | ▼ -197.4% |
| 2019 | -0.05x | ₩-5.94 Billion | ₩118.27 Billion | ▲ +75.0% |
| 2018 | -0.20x | ₩-7.30 Billion | ₩36.31 Billion | ▼ -754.6% |
| 2017 | 0.03x | ₩1.12 Billion | ₩36.43 Billion | ▲ +109.2% |
| 2016 | -0.33x | ₩-4.88 Billion | ₩14.58 Billion | ▼ -3209.8% |
| 2015 | -0.01x | ₩-204.05 Million | ₩20.19 Billion | — |